Overview

Dose-escalation Study of Oral CX-4945

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Cylene Pharmaceuticals